skip to content


AZ acalabrutinib submission accepted by US FDA

02 August 2017 07:30

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, have announced that the US Food and Drug Administration has accepted and granted priority review for the new drug application for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.

AstraZeneca said the NDA was based on results from the phase II ACE-LY-004 clinical trial, which evaluated the safety and efficacy of acalabrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) who had received at least one prior therapy.

It said this followed the FDA's recent breakthrough therapy designation for acalabrutinib.

Story provided by

Related Company: AZN

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.